RHY — Rhythm Biosciences Income Statement
0.000.00%
Last trade - 00:00
- AU$26.16m
- AU$24.94m
- AU$0.23m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | AAS | AAS | AAS | AAS | AAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.141 | 0.046 | 0.014 | 0.025 | 0.228 |
Cost of Revenue | |||||
Gross Profit | -1.48 | -1.35 | -2.18 | -0.172 | -0.327 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.71 | 4.06 | 7.73 | 11.2 | 11.5 |
Operating Profit | -3.57 | -4.02 | -7.72 | -11.2 | -11.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.55 | -4.02 | -6.61 | -8.79 | -8.22 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.55 | -4.02 | -6.61 | -8.79 | -8.22 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.55 | -4.02 | -6.61 | -8.79 | -8.22 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.55 | -4.02 | -6.61 | -8.79 | -8.22 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.022 | -0.04 | -0.035 | -0.041 | -0.037 |